5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases

Volumn 13, Issue 12, 2013, Pages 1050-1056

  Bhattacharya, Sujit K ^a,b   Sur, Dipika ^a   Ali, Mohammad ^c   Kanungo, Suman ^a   You, Young Ae ^c   Manna, Byomkesh ^a   Sah, Binod ^c   Niyogi, Swapan K ^a   Park, Jin Kyung ^c   Sarkar, Banwarilal ^a   Puri, Mahesh K ^c   Kim, Deok Ryun ^c   Deen, Jacqueline L ^d   Holmgren, Jan ^e   Carbis, Rodney ^c   Dhingra, Mandeep Singh ^f   Donner, Allan ^g   Nair, G Balakrish ^a   Lopez, Anna Lena ^c,h   Wierzba, Thomas F ^c   Clemens, John D ^c,i,j   more..

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^c International Vaccine Institute   (South Korea)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Shantha Biotechnics Limited   (India)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIVALENT KILLED WHOLE CELL ORAL CHOLERA VACCINE; CHOLERA VACCINE; INACTIVATED VACCINE; PLACEBO; SHANCHOL; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHOLERA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESCHERICHIA COLI K 12; FOLLOW UP; HUMAN; INCIDENCE; INDIA; INFANT; INFECTION RATE; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; CLUSTER ANALYSIS; DIARRHEA; DOUBLE-BLIND METHOD; HUMANS; INDIA; INFANT; PLACEBOS; VACCINATION; VACCINES, INACTIVATED; VIBRIO CHOLERAE O1;

EID: 84887624420     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70273-1     Document Type: Article

References (24)

1. Ali M, Lopez AL, You YA, et al. The global burden of cholera. Bull World Health Organ 2012, 90:209. 18A.
2. Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG Economic burden of cholera in the WHO African region. BMC Int Health Hum Rights 2009, 9:8.
3. Clemens JD Vaccines in the time of cholera. Proc Natl Acad Sci 2011, 108:8529-8530.
4. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
5. Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994, 344:1273-1276.
6. van Loon FP, Clemens JD, Chakraborty J, et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996, 14:162-166.
7. Sur D, Kanungo S, Sah B, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 2011, 5:e1289.
8. Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1694-1702.
9. Ansaruzzaman M, Bhuiyan NA, Nair BG, et al. Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis 2004, 10:2057-2059.
10. The treatment of diarrhoea: a manual for physicians and other senior health workers, 4th revision 2005, WHO, World Health Organization, Geneva.
11. Reid N, Crepeau H Influence functions for proportional hazards regression. Biometrika 1985, 72:1-9.
12. Lin D, Wei L, Ying Z Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993, 80:557-572.
13. Lin DY, Wei LJ The robust inference for the proportional hazards model. J Am Stat Assoc 1989, 84:1074-1078.
14. Lee EW, Wei LJ, Amato D Cox-type regression analysis for large numbers of small groups of correlated failure time observations 1992, 237-247. Kluwer Academic, Netherlands.
15. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM Oral vaccines for preventing cholera. Cochrane Database Syst Rev 2011, 3. CD008603.
16. Lucas M, Deen JL, von Seidlein L, et al. High-level effectiveness of a mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005, 352:757-767.
17. Khatib AM, Ali M, von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 2012, 12:837-844.
18. Anh DD, Lopez AL, Thiem VD, et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011, 5:e1006.
19. Thiem VD, Deen JL, von Seidlein L, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006, 24:4297-4303.
20. Plotkin SA Correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
21. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85:117-128.
22. WHO. Cholera: mechanism for control and prevention. WHA 64.15. Sixty-fourth World Health Assembly; Geneva, Switzerland; May 24, 2011.
23. WHO. Meeting report: WHO technical working group on creation of an oral cholera vaccine stockpile. Geneva, Switzerland; April 26-27, 2012.
24. Holmgren J A case for control of cholera in Africa by vaccination. Lancet Infect Dis 2012, 12:818-819.